Skip to main
  1. Stocks
  2. Lantheus Holdings
  3. Forecast
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is supported by a diversified radiopharmaceutical and precision-diagnostics franchise, led by PYLARIFY, DEFINITY, and Neuraceq, that continues to deliver broad-based revenue and earnings beats, including 1Q26 sales of $377.3 million and gross margin of 67.0%. The positive thesis is reinforced by multiple near-term catalysts, including FDA approval for PYLARIFY TruVu in March, tentative approval for PNT2003, and PDUFA decisions for LNTH-501 and MK6240, while the FDA’s CRL for LNTH-2501 did not raise concerns about safety, efficacy, or the company’s submitted data. With 2026 guidance reiterated conservatively and a path toward 2027 re-acceleration through stronger reimbursement, improved manufacturing efficiency, and potential royalty contributions from Flyrcado and Pylclari, the stock appears de-risked and positioned for margin and growth expansion.

Bears say

Lantheus Holdings is viewed negatively because its business is highly concentrated in PYLARIFY and DEFINITY, which represented over 80% of total sales in 2022, leaving the company vulnerable to any disruption in either platform. Pricing pressure from more aggressive competitors, slower-than-expected PYL stabilization into 1H26, and uncertainty around “PYL 2.0” approval or TPT status beyond Oct. 2026 all threaten the company’s growth trajectory and commercial footprint. The outlook is further weakened by execution risk tied to the LMI/Evergreen integrations, leadership transitions, and dependence on third-party payors and Medicare, while any break in its just-in-time radiopharmaceutical supply chain could quickly disrupt operations.

Lantheus Holdings (LNTH) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction

Get the latest Lantheus Holdings (LNTH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lantheus Holdings (LNTH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 5 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $111.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $111.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction

Get the latest Lantheus Holdings (LNTH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lantheus Holdings (LNTH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LNTH stock data and trends